Literature DB >> 23826598

FibroScan® and transient elastography.

William Kemp1, Stuart Roberts.   

Abstract

The use of non-invasive tests to stage the severity of liver disease (ie. scarring) is now well established in the management of patients with chronic liver disease. This is because assessment of liver scarring provides prognostic information and assists in establishing treatment priorities. One such technique, transient elastography (TE), is a simple, safe and efficient way to estimate liver scarring. FibroScan® (EchoSens, Paris) is the most popular non-invasive device used to assess liver 'hardness' (or stiffness) via TE in Australia. When performed in the appropriate clinical setting, TE provides a reliable method of detecting cirrhosis and excluding significant fibrosis, particularly when the results are supported by clinical and laboratory data.

Entities:  

Mesh:

Year:  2013        PMID: 23826598

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  9 in total

1.  Measurement of Liver Stiffness with 2D-Shear Wave Elastography (2D-SWE) in Bariatric Surgery Candidates Reveals Acceptable Diagnostic Yield Compared to Liver Biopsy.

Authors:  Tannaz Jamialahmadi; Mohsen Nematy; Ali Jangjoo; Ladan Goshayeshi; Reza Rezvani; Kamran Ghaffarzadegan; Mehdi Jabbari Nooghabi; Payman Shalchian; Mahtab Zangui; Zeinab Javid; Saeid Doaei; Farnood Rajabzadeh
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

2.  The Association Between Chronic Plaque Psoriasis and Nonalcoholic Fatty Liver Disease in Indian Patients: Results of a Pilot Study.

Authors:  Vikram K Mahajan; Narvir S Chauhan; Baldev S Rana; Karaninder S Mehta; Sheenam Hooda; Pushpinder S Chauhan; Amisha Kukreja
Journal:  J Clin Exp Hepatol       Date:  2021-12-03

Review 3.  The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature.

Authors:  Max M Puthenpura; Vishal Patel; John Fam; Leon Katz; David S Tichansky; Stephan Myers
Journal:  Obes Surg       Date:  2020-09-26       Impact factor: 4.129

4.  False-positive paracetamol levels in a patient with hyperbilirubinaemia: clinical perspectives.

Authors:  Joel James; Madelena Stauss; Arvind Ponnusamy; Martin Myers
Journal:  BMJ Case Rep       Date:  2020-06-30

5.  Longitudinal study of health, disease and access to care in rural Victoria: the Crossroads-II study: methods.

Authors:  Kristen M Glenister; Lisa Bourke; Leslie Bolitho; Sian Wright; Stuart Roberts; William Kemp; Leigh Rhode; Ravi Bhat; Sönke Tremper; Dianna J Magliano; Mike Morgan; Rodrigo Mariño; William Adam; David Simmons
Journal:  BMC Public Health       Date:  2018-05-30       Impact factor: 3.295

6.  Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis.

Authors:  Nigel Cook; Andreas Geier; Andreas Schmid; Gideon Hirschfield; Achim Kautz; Jörn M Schattenberg; Maria-Magdalena Balp
Journal:  JHEP Rep       Date:  2020-02-01

7.  The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.

Authors:  Stefanie Slot; Niels W C J van de Donk; René H J Otten; Bouke J H Boden; Josée Zijlstra; Pieter G H M Raijmakers; Sonja Zweegman
Journal:  Cancer Imaging       Date:  2021-04-20       Impact factor: 3.909

8.  Using FIB-4 score as a screening tool in the assessment of significant liver fibrosis (F2) in patients with transfusion-dependent beta thalassaemia: a cross-sectional study.

Authors:  Padmapani Padeniya; Dileepa Senajith Ediriweera; Arjuna P De Silva; Madunil Anuk Niriella; Anuja Premawardhena
Journal:  BMJ Open       Date:  2022-09-26       Impact factor: 3.006

9.  Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers.

Authors:  Kevin J Fagan; Katharine M Irvine; Brett C McWhinney; Linda M Fletcher; Leigh U Horsfall; Lambro Johnson; Peter O'Rourke; Jennifer Martin; Ian Scott; Carel J Pretorius; Jacobus P J Ungerer; Elizabeth E Powell
Journal:  BMC Gastroenterol       Date:  2014-05-22       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.